Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

CBD Levels In Products May Not Be What They Say, New Digital Citizens Alliance Research Finds

Lack Of Federal Standards Coupled With Inaccurate Labels Call Safety And Quality Of CBD Products Into Question

Americans Are Unaware Of CBD Wild West And Willing To Replace Prescription And OTC Medicines With CBD


News provided by

Digital Citizens Alliance

Mar 05, 2020, 09:00 ET

Share this article

Share toX

Share this article

Share toX

WASHINGTON, March 5, 2020 /PRNewswire/ -- As millions of Americans increasingly rely on cannabidiol (CBD) products – to the tune of more than $1 billion in sales -- to help with pain, depression, anxiety and even cancer, new Digital Citizens Alliance (Digital Citizens) research shows that CBD levels listed on product labels may often be inaccurate, putting consumers at risk and highlighting the need for federal standards and regulation by the U.S. Food and Drug Administration (FDA).

More than half of the products purchased and tested by Digital Citizens contained CBD levels that were 20 percent higher or lower than what was listed on the packaging. In a number of cases, CBD levels were less than half, with some containing less than 10 percent, of what the label claimed. That means consumers were receiving essentially a placebo.

What makes the findings alarming is that many Americans who take CBD report they did so to replace a prescription medication to treat medical issues including pain, insomnia, anxiety, depression, and, even in some cases, cancer and Alzheimer's disease.

"CBD shows promise to treat pain, anxiety and seizures such as epilepsy. But the market can't be built on inaccurate CBD levels, misleading claims and a false sense of security about safety," said Tom Galvin, Executive Director of Digital Citizens. "For consumers to truly trust CBD, they need to know that products meet safety and quality standards backed up by the FDA." 

The Digital Citizens report, "CBD Confusion: How Consumers Can Be Misled and Why the Market Needs Adult Supervision Now," relied on the testing of dozens of CBD-infused products purchased online and at retail outlets. In addition, the Digital Citizens Alliance commissioned three national surveys to shed light on consumer's use of CBD, their understanding of CBD products and their attitudes toward government regulation.

CBD, which is the abbreviation for cannabidiol, is one of the primary extracts from hemp and marijuana. Unlike tetrahydrocannabinol (THC), CBD doesn't create a "high" when ingested. The FDA approved CBD to treat two forms of epilepsy in 2018, and that is the only federally approved usage of the extract. But that hasn't stopped the rapid consumer adoption of CBD-infused products to treat depression and anxiety and help with insomnia.

According to  a John Zogby Strategies survey of 2,506 American consumers commissioned by Digital Citizens, three in 10 Americans say they have tried CBD products, and of those, 82 percent call the emergence of the products a "positive" thing.

But the results of the Digital Citizens investigation and consumer research raise concerns that widespread use, a willingness to substitute CBD for prescription medication, and, anecdotal evidence that some small retailers mislead consumers into believing CBD is regulated creates a false sense of security that could have serious health implications. Here are the key findings of the Digital Citizens investigation:

  • Many products that Digital Citizens had tested had significantly less CBD than claimed on the label. Two products, Talyoni Youthful Glow 850mg Tincture (6 percent of what label said) and Relax Dried Fruit Apricot CBD 750mg (3 percent of what label said) had little CBD at all.
  • Seventy percent of those using CBD products said they do so "as an alternative to taking other medication." Nearly half (46 percent) said it was a replacement for a prescription medication.
  • Americans are turning to CBD as a replacement for medication treating serious health issues. When asked, "If you used a CBD product in replacement of a medication, what type of medical issue were you treating?," CBD users not surprisingly answered pain (53 percent), anxiety (48 percent), and depression (29 percent). They also said they used CBD in place of medication for cancer (9 percent), Alzheimer's disease (7 percent) and diabetes (7 percent).
  • Only 1 in 4 Americans who have purchased products containing CBD know that it's largely unregulated at the federal level. This lack of awareness about the unregulated nature of CBD suggests consumers believe the products meet standards for safety and quality.

The CBD market is in desperate need of adult supervision. The products live in a legal and regulatory no-man's land at the federal level but are widely sold all over the United States. It is up to Congress, the FDA and FTC to step in. And if they don't, Congress should mandate they do with legislation. Digital Citizens calls for the following policy steps:

  • It's vital that we learn more about CBD. Users of CBD swear by its therapeutic properties. Eighty-two percent of users call the emergence of CBD a positive thing. But we need more testing, and more funding for research, to know the long-term impacts, both positive and negative.
  • The FDA, by its own admission, is way behind in providing a CBD regulatory roadmap. But that admission is no excuse. If CBD is as therapeutic as its users claim it is, then the FDA's delay is a hindrance to Americans' health. The delay also hinders research and testing. The only entity that can unstick the FDA is Congress which should continue to demand action.
  • The FDA cannot send a warning letter once or twice a year and expect to tame the Wild West marketplace. The FDA and FTC must act to consistently protect consumers by flagging and punishing those who make fraudulent health and safety claims.

Media Contact:
Adam Benson
[email protected]
202.999.9104

About DCA
The Digital Citizens Alliance is a nonprofit, 501(c)(6) organization that is a consumer- oriented coalition focused on educating the public and policymakers on the threats that consumers face on the Internet. Digital Citizens wants to create a dialogue on the importance for Internet stakeholders— individuals, government and industry—to make the Web a safer place. Based in Washington, DC, the Digital Citizens Alliance counts among its supporters: private citizens, the health, pharmaceutical and creative industries as well as online safety experts and other communities focused on Internet safety. Visit us at www.digitalcitizensalliance.org

SOURCE Digital Citizens Alliance

Related Links

http://www.digitalcitizensalliance.org

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Brokers and Digital Secondary Markets are Driving up Costs for Concert and Sports Tickets and Other Goods and Services, Digital Citizens Alliance Investigation Finds

Secondary markets can provide consumers with helpful options that were unavailable just decades ago, but they can also warp access and distort prices ...

More Releases From This Source

Explore

Cannabis

Cannabis

Health Care & Hospitals

Health Care & Hospitals

Supplementary Medicine

Supplementary Medicine

Not For Profit

Not For Profit

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.